Sommaire

• • ·European Commission processes fail again

    Page :1

     
• • ·The good, the bad, and the ugly: effect of regulations on cancer research

    Page :2-3

    Richard Sullivan

     
• • ·ERBB2 status and outcome of endocrine treatment

    Page :4-5

    WR Miller

     
• • ·Nomograms as clinicobiological predictors of survival in glioblastoma

    Page :5-6

    Markus Bredel

    
• • ·Improving treatment of pancreatic cancer

    Page :7-8

    Philip A Philip

     
• • ·Long-term outcomes of aromatase inhibition for breast cancer

    Page :8-10

    Masakazu Toi

    
• • ·Call for papers: lung cancer, Storyboard, and From the Archives

    Page :10

    Lidia Siemaszkiewicz

    
• • ·Erratum

    Page :10

    
• • ·Pharmaceutical downsizing and oncology drug development

    Page :11

    Kathryn Senior

     
• • ·Plan to improve cancer survival in England

    Page :12

    Susan Mayor

     
• • ·American Society of Hematology Annual Meeting

    Page :13

    Janet Fricker

    Plan Plan  
• • ·San Antonio Breast Cancer Symposium

    Page :14

    David Collingridge

    Plan Plan  
• • ·New treatment for ERBB2-expressing tumours

    Page :15

    Sharan Prakash Sharma

    
• • ·Cryoablation provides pain relief

    Page :15

    Emma Hitt

     
• • ·Palliation using hypofractionated radiotherapy

    Page :16

    Sanjit Bagchi

    
• • ·Combined treatment targets chemorefractory tumours

    Page :16

    Marta Paterlini

     
• • ·Minocycline decreases severity of cetuximab rash

    Page :17

    Paula Gould

     
• • ·Lenalidomide combination in multiple myeloma

    Page :17

    Kaushal Raj Pandey

    
• • ·Vaccine shows no benefit for colorectal-cancer metastases

    Page :18

    Mary Beth Nierengarten

     
• • ·Hormone treatment ineffective in ovarian cancer

    Page :18

    Vicki Brower

    
• • ·Exit Ghost

    Page :19-20

    Talha Burki

     
• • ·Introspection

    Page :20-22

    Emma Cannell, Li Wan

     
• • ·Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

    Page :23-28

    Birgitte B Rasmussen, Meredith M Regan, Anne E Lykkesfeldt, Patrizia Dell’Orto, Barbara Del Curto, Katrine L Henriksen, Mauro G Mastropasqua, Karen N Price, Eliane Méry, Magali Lacroix-Triki, Stephen Braye, Hans J Altermatt, Richard D Gelber, Monica Castiglione-Gertsch, Aron Goldhirsch, Barry A Gusterson, Beat Thürlimann, Alan S Coates, Giuseppe Viale, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups

    Résumé Résumé Plan Plan   
• • ·Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3

    Page :29-38

    Thierry Gorlia, Martin J van den Bent, Monika E Hegi, René O Mirimanoff, Michael Weller, J Gregory Cairncross, Elizabeth Eisenhauer, Karl Belanger, Alba A Brandes, Anouk Allgeier, Denis Lacombe, Roger Stupp

    Résumé Résumé Plan Plan   
• • ·Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial

    Page :39-44

    Stefano Cascinu, Rossana Berardi, Roberto Labianca, Salvatore Siena, Alfredo Falcone, Enrico Aitini, Sandro Barni, Francesco Di Costanzo, Elisa Dapretto, Giuseppe Tonini, Chiara Pierantoni, Salvatore Artale, Silvia Rota, Irene Floriani, Mario Scartozzi, Alberto Zaniboni, for the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

    Résumé Résumé Plan Plan  
• • ·Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

    Page :45-53

    The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group ‡

    Résumé Résumé Plan Plan   
• • ·Venous thromboembolism in cervical cancer

    Page :54-60

    Lisa Barbera, Gillian Thomas

    Résumé Résumé Plan Plan  
• • ·Gastroenteropancreatic neuroendocrine tumours

    Page :61-72

    Irvin M Modlin, Kjell Oberg, Daniel C Chung, Robert T Jensen, Wouter W de Herder, Rajesh V Thakker, Martyn Caplin, Gianfranco Delle Fave, Greg A Kaltsas, Eric P Krenning, Steven F Moss, Ola Nilsson, Guido Rindi, Ramon Salazar, Philippe Ruszniewski, Anders Sundin

    Résumé Résumé Plan Plan  
• • ·Possible mechanisms of disease development in tuberous sclerosis

    Page :73-79

    Jaroslaw Jozwiak, Sergiusz Jozwiak, Pawel Wlodarski

    Résumé Résumé Plan Plan  
• • ·Ovarian ablation as a non-surgical treatment for breast cancer

    Page :80

    John R Benson